Commission to publish details of EU product "safety feature" later this year
This article was originally published in Scrip
Later this year pharmaceutical firms should find out exact details of the safety features they will have to affix to their prescription drugs in order to comply with EU legislation aimed at preventing falsified medicines entering the legitimate supply chain.
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
A number of countries are resorting to extreme measures such as export bans to preserve stocks of medicines for the COVID-19 pandemic. Belgium is among the latest to impose an export prohibition, but might it fall foul of the EU’s export regulations?